New Delhi, May 26 (PTI) Aurobindo Pharma on Monday reported a marginal dip in its consolidated profit after tax to Rs 903 crore for the fourth quarter ended March 2025.

The Hyderabad-based drug maker posted a profit after tax (PAT) of Rs 907 crore in the January-March quarter of FY24.

Also Read | What Is Bharat Forecast System? Know All About the World's Highest-Resolution Weather Model Launched by the Ministry of Earth Sciences for Accurate Panchayat-Level Forecasts in India.

Its total revenue from operations stood at Rs 8,382 crore for the fourth quarter compared to Rs 7,580 crore in the year-ago period, Aurobindo Pharma said in a regulatory filing.

For the full year ended March 31, 2025, the company said its PAT rose 10 per cent to Rs 3,484 crore against Rs 3,169 crore in FY24.

Also Read | Bodoland Lottery Result Today, May 26, 2025: Assam State Lottery Sambad Monday Lucky Draw Results Declared, Check Winners List With Ticket Numbers.

The total revenue from operations rose to Rs 31,724 crore last fiscal from Rs 29,002 crore in 2023-24.

"We are pleased to deliver another quarter and year of all-time high sales and EBITDA, reflecting the strength of our core businesses, consistent volume-led growth, and the depth of our differentiated product portfolio," Aurobindo Pharma Vice-Chairman and MD K Nithyananda Reddy said.

The drug firm's European operations continue to perform exceptionally well, moving steadily towards the USD 1 billion revenue milestone, he added.

"Backed by our ongoing capacity enhancements we remain firmly positioned to sustain our trajectory and create long-term value for our stakeholders," Reddy said.

Aurobindo Pharma shares on Monday ended 1.43 per cent down at Rs 1,179.35 apiece on BSE.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)